ERN1/IRE1 (R728A)
Sign in to save this workspaceERN1 · Variant type: point · HGVS: p.R728A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 76.9% | 23.1% | 88.97 |
| 2 | Pacritinib | 30.7% | 69.3% | 88.64 |
| 3 | Defactinib | 18.5% | 81.5% | 92.68 |
| 4 | Selpercatinib | 17.4% | 82.6% | 96.72 |
| 5 | Abemaciclib | 15.0% | 85.0% | 91.48 |
| 6 | Fedratinib | 12.4% | 87.6% | 96.21 |
| 7 | Palbociclib | 9.0% | 91.0% | 98.75 |
| 8 | Neratinib | 6.7% | 93.3% | 93.18 |
| 9 | Sorafenib | 6.4% | 93.6% | 96.72 |
| 10 | Pexidartinib | 6.4% | 93.6% | 99.49 |
| 11 | Asciminib | 5.8% | 94.2% | 100.00 |
| 12 | Sunitinib | 5.5% | 94.5% | 91.73 |
| 13 | Erdafitinib | 5.5% | 94.5% | 95.71 |
| 14 | Pirtobrutinib | 5.1% | 94.9% | 99.49 |
| 15 | Tivozanib | 4.8% | 95.3% | 92.42 |
| 16 | Mobocertinib | 4.6% | 95.4% | 97.22 |
| 17 | Quizartinib | 4.0% | 96.0% | 99.50 |
| 18 | Canertinib | 3.8% | 96.2% | 96.49 |
| 19 | Rabusertib | 3.2% | 96.8% | 98.74 |
| 20 | Capivasertib | 2.2% | 97.8% | 96.48 |
| 21 | Avapritinib | 2.0% | 98.0% | 97.73 |
| 22 | Erlotinib | 1.7% | 98.3% | 99.75 |
| 23 | Tucatinib | 1.7% | 98.3% | 99.75 |
| 24 | Pemigatinib | 1.5% | 98.5% | 98.23 |
| 25 | Tenalisib | 1.4% | 98.6% | 97.98 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 76.9% | — | — |
| Pacritinib | 30.7% | — | — |
| Defactinib | 18.5% | — | — |
| Selpercatinib | 17.4% | — | — |
| Abemaciclib | 15.0% | — | — |
| Fedratinib | 12.4% | — | — |
| Palbociclib | 9.0% | — | — |
| Neratinib | 6.7% | — | — |
| Sorafenib | 6.4% | — | — |
| Pexidartinib | 6.4% | — | — |
| Asciminib | 5.8% | — | — |
| Sunitinib | 5.5% | — | — |
| Erdafitinib | 5.5% | — | — |
| Pirtobrutinib | 5.1% | — | — |
| Tivozanib | 4.8% | — | — |
| Mobocertinib | 4.6% | — | — |
| Quizartinib | 4.0% | — | — |
| Canertinib | 3.8% | — | — |
| Rabusertib | 3.2% | — | — |
| Capivasertib | 2.2% | — | — |
| Avapritinib | 2.0% | — | — |
| Erlotinib | 1.7% | — | — |
| Tucatinib | 1.7% | — | — |
| Pemigatinib | 1.5% | — | — |
| Tenalisib | 1.4% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.4ms